BUZZ-Vir jumps on positive data from early-stage trials for tumor treatments** Drug developer Vir Biotechnology's VIR.O shares rise 33.2% to $10.50 premarket
** Co says its drugs VIR-5818 and VIR-5500 showed compelling response in patients with various solid tumors during early-stage trials
** Says VIR-5818 showed tumor shrinkage in 50% of patients with various HER2 positive cancers
** HER2 is a protein that stimulates quick growth of cancer cells
** VIR says all 12 patients who took VIR-5500 showed a decline in prostate-specific antigen levels, which indicate the presence of prostate cancer
** Up to last close, stock down 25.6% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments